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Abstract Human pregnancy is a metabolic and immune
challenge for the mother who has to accommodate in her
womb a semi-allogeneic fetus whose energy needs increase
tremendously with gestation. Recent compelling research
has suggested that proper inflammatory changes and
oxidative balance are a requisite for successful pregnancy.
The placenta is an integral component of this inflammatory
response as it actively produces a variety of cytokines and
immunomodulatory hormones. In preeclampsia, a life-
threatening disorder of pregnancy that is characterized by
widespread damage and dysfunction of the maternal
endothelium, placental oxidative stress and aberrant cyto-
kine expression induces an exaggerated maternal systemic
inflammatory response to pregnancy.
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Introduction
Human pregnancy imposes a massive stress to the maternal
body, which has to accommodate the increasing energy
needs of the developing fetus at the expense of its own
needs. Therefore, several physiologic and metabolic
changes take place in the maternal body to adapt to such
a challenge. The most striking physiologic alteration during
pregnancy, apart from the evident weight gain as a
consequence of fat and protein deposition in maternal
stores, is the increase in blood volume, which is needed for
extra blood flow to the uterus and increased perfusion of
other organs, especially the kidneys. The pregnant uterus
undergoes important tissue and vascular remodeling, the
most remarkable of which is the transformation of the
uterine spiral arteries into low-resistance flow vessels that
enable large volumes of blood to gain access to the
placental intervillous space [1]. Additional metabolic
changes, such as increased red blood cell counts, insulin
resistance and elevated cardiac output further guaranty that
the placental villous tree bathes in a nutrient- and oxygen-
rich milieu.
The success of pregnancy requires an appropriate
immunological interplay between the mother and the
developing fetus, as the latter, which expresses paternal
antigens, is considered to be a semi-allograft to the maternal
immune system [2]. Thus, mechanisms have developed to
allow the fetal entity to escape from maternal immune
attack, and above all, avoid rejection. To begin with, the
fetus is physically secluded from the maternal immune
system by the protective shell of embryonic trophectoderm-
derived trophoblast cells, which make up the placenta and
the chorionic membrane. Most interestingly, the placenta has
been identified as a site of immune privilege. This tissue is
the source of production of many immunomodulatory
hormones and cytokines, and one prevalent hypothesis is
that several of these factors released at the feto–maternal
interface or into the maternal blood stream contribute to the
regulation of the local and systemic immune changes
required for a successful pregnancy. By contrast, aberrant
placental production of these factors has been shown to be
associated with pregnancy-related disorders or even failed
pregnancies. The action of several cytokines in the success of
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pregnancy and in the development of preeclampsia will be
reviewed here.
The immunology of pregnancy
The placenta, which is in direct contact with maternal cells
in the uterine wall and with maternal blood, is an important
immunological barrier between maternal and fetal antigens.
This tissue lacks expression of the conventional poly-
morphic major histocompatibility molecules (MHC) class I,
human leukocyte antigen (HLA)-A and HLA-B, and class
II [3], and thus, is protected from cytotoxic T lymphocyte
(CTL)-mediated destruction. To avoid killing by natural
killer (NK) cells, which are programmed to recognize
HLA-null cells, trophoblast cells express instead a combi-
nation of the nonclassical MHC molecules HLA-G [4],
HLA-E, and HLA-F [5]. Whereas the role of HLA-F in
pregnancy still awaits elucidation, accumulating research
has provided convincing evidence that HLA-G and HLA-E
possess immunosuppressive properties, especially towards
NK cells and subsets of T lymphocytes, and the idea that
placental HLAs facilitate pregnancy, in part, by inhibiting
maternal immune cytotoxic responses towards placental
cells is now well established [6, 7]. However, a different
regulatory mechanism must apply to decidual NK cells,
which constitute 50 to 70% of all maternal immune cells
present in the pregnant uterus, as these cells do not appear
to possess lytic activity [8]. Instead, they are thought to
positively regulate pregnancy through secretion of cyto-
kines and angiogenic factors, which have crucial actions on
the vascular and decidual transformations occurring in the
uterine wall during the early weeks of pregnancy [9–11].
Nevertheless, their regulation might also be mediated by
HLA-G and by HLA-C, also present in high amounts on
extravillous trophoblasts invading the pregnant uterus [12,
13].
In addition to strategies conferring a relative immune
“invisibility” to the placenta, adjustments in the maternal
immune system have been suggested to help in sustaining a
successful pregnancy. The concept of a maternal CD4-
positive T helper cell (Th) 2-biased immunity in pregnant
women has been appreciated for over a decade [14]. Th2
immunity is characterized by the dominance of humoral
immune responses over cell-mediated, more destructive
responses, more likely to be detrimental to the fetal
allograft. CD4-positive Th2 lymphocytes develop from
naïve T helper cells in the presence of interleukin (IL)-4
and IL-10, whereas Th1 cells arise when IL-2 and
interferon (IFN)-γ are present. In turn, Th1 and Th2
lymphocytes express a panel of membrane-bound or
soluble immunomodulatory mediators, which influence
the activity of other cells of the adaptive immune system,
therefore controlling the immune response. A type 2 bias
seems to take place both in the intrauterine milieu and in
the systemic maternal circulation during pregnancy. It has
been reproducibly demonstrated that the placental bed
encloses a high incidence of the Th2 factors IL-4 and IL-
10 [15–19]. Several isoforms of the immunosuppressive
transforming growth factor (TGF)β have also been local-
ized in the placenta, adding to the immune privilege of this
tissue [20–22]. Trophoblast cells themselves contribute to
the generation of this cytokine milieu as they spontaneously
secrete these immunoregulatory molecules, locally, but also
into the intervillous space where these may likely partici-
pate in the constitution of the peripheral type 2 response.
By contrast, type 1 cytokines appear to be marginally
expressed or completely absent from the feto–maternal
interface [23, 24]. Moreover, the profile of cytokine
synthesized by maternal peripheral blood lymphocytes
during pregnancy further sustains the development of type
2 immune responses [25]. Conversely, failure to generate a
Th2 cytokine milieu, or alternatively, a Th1 cytokine
environment has been associated with poor pregnancy
outcome [26–28]. However, this long-standing paradigm
has been recently disputed [29], as the networks of
cytokines targets and actions have become increasingly
intricate.
Normal pregnancy and inflammation
A series of intriguing findings have lead to the suggestion
that pregnancy is, in fact, a condition of controlled mild
maternal systemic inflammation, during which cells of the
innate immune system display activated phenotypes [30–
32] and circulating levels of particular pro-inflammatory
cytokines, such as tumor necrosis factor (TNF)α, IL-6, and
IL-1 are raised compared to nonpregnant women [33, 34].
By some aspects, the inflammatory changes in peripheral
blood leukocytes were found to be similar to those
occurring in patients with sepsis [30]. In addition, mono-
cytes from normal pregnant women were shown to be
primed to produce the potent Th1 cytokine IL-12 [35],
fueling the debate on the strict dependence on a type 1 vs
type 2 adaptive immunity in pregnancy. What is more
confounding is the fact that trophoblast cells as well appear
to be the source of production of these pro-inflammatory
cytokines [36–41]. In vitro, in a dually perfused placental
cotyledon, most of placental TNFα was released to the
maternal side [42], confirming the importance of placen-
tally produced inflammatory mediators in the induction of
the maternal systemic changes. Yet, generalized maternal
inflammation is not associated with illness in pregnancy,
but has been suggested to be part of the mother’s adaptation
to pregnancy and might be crucial for successful pregnancy
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by not only potentially compensating for a suppressed
maternal adaptive immune system and therefore help
protect against infection, but also by promoting the
physiologic and metabolic changes taking place in the
mother’s body [43].
Preeclampsia
Preeclampsia is a serious complication of the second half of
human pregnancy, which can have harmful effects on the
immediate and long-term health of the mother and the baby
[44, 45]. This disease is characterized by multiple maternal
disturbances, among which the more prominent symptoms
are de novo hypertension, proteinuria, and edema.
Additional metabolic dysfunctions may be present, such
as activation of the clotting system, impaired liver function,
renal failure or pulmonary edema, in particular, in cases of
severe, early onset disease [46]. In the absence of
intervention, preeclampsia can progress in generalized
convulsions or eclampsia. The symptoms resolve only once
the placenta is removed, and thus, preeclampsia remains
one of the most common reasons for induced preterm
delivery.
While the etiology of the disorder is still elusive, it is
quite clear that it requires a placenta to develop. Risk
factors are known and include primiparity, multiple
pregnancies, a previous history of preeclampsia, and
chronic medical conditions such as obesity, hypertension,
vascular disease, or diabetes [47]. However, there is no
definitive predictive factor and no preventive treatment
available so far. There may undoubtedly be a genetic
component at the basis of some cases of preeclampsia, at
least in those with a familial history [48, 49]. However,
such a genetic cause has not been convincingly demon-
strated until now, most likely because polymorphisms in
not only one but in several genes are likely to predispose to
the development of this complex multifactorial disease. On
the other hand, recent work clearly reveals that immune
maladaptation and overt activation of the maternal innate
immune system are involved in preeclampsia [50, 51].
Remarkably, although the maternal symptoms of pre-
eclampsia appear very heterogeneous at first sight, they
can all be ascribed to a generalized endothelium dysfunc-
tion [52], which is undeniably part of this exaggerated
systemic inflammatory response to pregnancy [53].
Two-stage model of the disease
The symptomatic phase of the disease is, in reality, the
second step of a two-stage pathological process, which has
its origins in the placenta and occurs during the first weeks
of pregnancy [54, 55]. There is evidence of inadequate
immunological interactions at the feto–maternal interface
already very early in pregnancy. It has been described that
HLA-G is under-expressed in preeclamptic placentas [56–
58], whereas certain combinations of placental HLA-C and
their receptors on maternal NK cells appear to be
selectively linked to the risk of developing the disease
[13, 59]. Moreover, the number and distribution of macro-
phages in placental beds are significantly altered in
preeclampsia in comparison to normal pregnancy [60–62].
Furthermore, it was also shown that activated macrophages
have the potential to induce apoptosis of extravillous
trophoblasts in vitro [63]. Increased trophoblast cell death
is believed to be central to the impaired placentation that is
observed in most cases of preeclampsia. These cells detach
from the tip of the primitive trophoblastic outgrowths of the
embryo, the anchoring villi, soon after embryo implanta-
tion, and actively invade the uterine wall around and into
the spiral arteries, to initiate vessel remodeling and establish
the uteroplacental circulation. In normal pregnancy, extra-
villous trophoblasts migrate deep into the decidual part of
the arteries and ultimately adopt an endothelial cell-like
phenotype and replace their musculo-endothelial lining.
The arteries are thus transformed into low-resistance, high-
flow channels that provide the appropriate blood flow to the
fetus. Preeclampsia is associated with widespread apoptosis
of cytotrophoblasts that invade the uterus [64]. Correspond-
ingly, extravillous trophoblasts invasion is abnormally
shallow, and the remodeling and enlargement of the spiral
arteries is restricted to their placental–proximal part [65,
66].
It has been hypothesized that as a consequence of failed
remodeling, blood supply to the placenta is greatly reduced,
and this may trigger placental hypoxia [67, 68]. An
alternative interpretation of the histopathologic findings
has proposed that after incomplete modification of the
spiral arteries by the extravillous cytotrophoblasts, these
retain a certain capacity to contract in their myometrial part.
Phases of contraction followed by relaxation would then
lead to cycles of hypoxia/reoxygenation within the placenta
[69]. Whatever mechanism at play, the end result would be
placental oxidative stress and dysfunction.
Oxidative stress occurs when the cellular levels of
reactive oxygen species (ROS) exceed the cell antioxidant
capacities. It has been reproducibly observed that ROS are
increased, and the levels of several detoxifying enzymes are
reduced in preeclamptic placentas, leading to damage of
cellular lipids and various other cellular components [70–
74]. Moreover, in vitro triggered oxidative stress of a
trophoblast cell line reproduced the placental abnormalities
of preeclampsia [75]. Deficient oxygenation and increased
oxidative stress most probably occur as early as week 10–
12 of gestation when maternal blood first gains access to
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the placenta; however, the antioxidant capacity of placental
cells might counteract or contain the insult for some time,
until the levels of ROS, by far, surpass the placental redox
capacity. Subsequently, placental damage and dysfunction
becomes disproportionate. Hence, preeclamptic placentas
are often aberrantly structured, with histological evidence
of vasculitis, thrombosis, and areas of ischemic or necrotic
tissue. These placentas also exhibit increased trophoblast
apoptosis [76, 77], a feature that can be reproduced in vitro
in models of placental hypoxia or hypoxia/reoxygenation
[78–80]. It has been proposed that unusual loads of
placental debris and toxic factors, among which pro-
inflammatory cytokines, are released in the intervillous
space, and in turn, interact with maternal endothelium and
cells of the innate immunity, causing the vast array of
maternal symptoms that distinguish the disease [81]. We
and others have shown that the amount of placental debris,
such as cell-free apoptotic DNA [82, 83] and syncytial
microparticles, is indeed elevated in peripheral blood of
women with preeclampsia [84, 85].
Cytokines in preeclampsia
It is generally agreed that preeclampsia is associated with
both local and systemic changes in type 1/type 2 cytokine
balance compared to normal pregnancy. Decidual lympho-
cytes and peripheral blood mononuclear cells from patients
with preeclampsia are generally primed to synthesize high
levels of the Th1 cytokines, IL-2, IL-12, and IFN-γ [86–
89]. On the other hand, they exhibit low spontaneous or
phytohemaglutinin-induced expression of the Th2 cyto-
kines IL-10 and IL-5 [90–92]. Whereas these findings
initially lead to the conclusion that a maternal T lympho-
cyte-mediated cytotoxic reaction against the fetal allograft
was possibly associated with, and maybe the cause of
preeclampsia, it is now believed that such a cytokine
environment rather reflects the state of exaggerated inflam-
mation that characterizes the disease. Monocytes and
granulocytes present an activated pattern of leukocyte
adhesion molecules on their surface and show an increased
incidence of basal or induced oxidative stress response
compared to their counterparts from normal pregnancy [30,
93]. Spontaneous monocytic cytokine expression is higher
in preeclampsia in comparison with normal pregnancy [94].
This is mirrored in the maternal plasma cytokine environ-
ment. The circulating levels of TNFα and IL-6, which are
already more elevated in healthy pregnant women com-
pared to nonpregnant controls, are further raised in patients
with preeclampsia [95–98]. There are also numerous
reports of increased serum or plasma levels of several other
pro-inflammatory cytokines and of their modulators, such
as, IL-2, IL-8, IL-12, IL-15, IL-18, IL-1 receptor antago-
nist, soluble IL-4 receptor, and soluble TNF receptor
(Table 1) [96, 99–104]. The increased levels of soluble
cytokine receptors found in patients with preeclampsia may
represent a protective response to increased cytokine
activity and be a marker for overt inflammation. However,
these findings remain very controversial as others did not
detect alterations in the levels of pro-inflammatory mole-
cules between healthy pregnant controls and preeclamptic
patients [104–106]. Of course, plasma cytokine milieu
does not reflect the strict contribution of the placenta, as
cytokine production by the dysfunctional maternal endo-
thelium and peripheral blood mononuclear cells is obvi-
ous. However, it is undoubted that placental contribution
is likely to be significant, as cytokine imbalance and
elevated expression of pro-inflammatory molecules is also
evident in preeclamptic placentas. Increased production of
TNFα, IL-1, and IFN-γ has been documented in these
placentas [107–110].
Oxidative stress and placental production
of pro- and anti-inflammatory cytokines
A recent set of data has demonstrated that placental
expression of many cytokines and soluble mediators of
inflammation is tightly regulated by the oxygen tension and
cellular oxidative stress that are imposed on the tissue.
They provide, therefore, a direct link between the aberrant
placental tissue oxygenation and altered cytokine patterns
observed in preeclamptic placentas. It was shown that
explants of placental villous tissue, derived from normal
term placentas, significantly enhance their production of
TNFα, IL-1α, and IL-1β when they are incubated in
hypoxia, in comparison with the levels produced upon
incubation in normoxia [111, 112]. The expression levels of
these cytokines are similarly raised under alternative culture
conditions which reduced oxygen availability, such as in
Table 1 Placentally produced inflammatory and immunomodulatory
cytokines in preeclampsia
Cytokines In placentaa In peripheral blooda
TNFα No change/increased Increased
IL-1 No change/increased No change
IL-6 No change/reduced Increased
IL-8 Increased Increased
IFN-γ Increased No change/increased
IL-12 Reduced Increased
IL-15 Reduced No change/increased
IL-10 Reduced No change/increased
IL-4 No change No change/reduced
a Changes relative to normal pregnancy. Contradictory data are
mentioned.
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the presence of an iron chelator or cobalt chloride. It is
interesting to note that late first trimester villous tissue also
responds to hypoxia by increasing pro-inflammatory cyto-
kine secretion, whereas early first trimester villous tissue is
relatively insensitive to the changes in oxygen tension
[111]. Furthermore, villous explants derived from pre-
eclamptic placentas were found to be equally sensitive to
the effect of hypoxia on TNFα and IL-1 expression [113].
Hypoxia/reoxygenation also increases TNFα synthesis
by placental villous tissue in vitro [114]. Notably, in this
particular experimental setting, hypoxia/reoxygenation was
shown to be a more potent inducer of cytokine secretion
than hypoxia alone. Finally, chemicals which trigger
placental oxidative stress also stimulates elevated TNFα
and IL-1 production by villous explants [112]. In this
context, it is interesting to note that in the presence of the
antioxidant vitamin C, the secretion of TNFα by term
placental villous explants is significantly reduced by 20%
(Fig. 1). In contrast, IL-1β secretion did not show such a
regulation. This would suggest that therapeutic interven-
tions with antioxidant agents could possibly be developed,
even though clinical trials with vitamin supplementation
have so far failed to prevent disease occurrence in women
at increased risk [115, 116].
Whether IL-6 expression is also controlled by oxygen
levels is still debatable. No hypoxia-driven changes in IL-6
synthesis by placental explants were documented. In
contrast, isolated cytotrophoblast cells derived from pre-
eclamptic placentas were shown to express higher levels of
this molecule than their normal counterparts and to respond
to hypoxia by further increasing IL-6 secretion [117].
These latter data seem to contradict the finding that
preeclampsia is associated with decreased placental IL-6
production [113, 118].
It is interesting to note that placental expression of
immunosuppressor cytokines also seems to be modulated
by oxygen tension. Cytotrophoblasts isolated from pre-
eclamptic placentas show a hypoxia-induced reduction in
IL-10 synthesis [117]. This feature is in agreement with the
description of deficient placental IL-10 production in
preeclampsia [119, 120]. Trophoblast expression of TGFβ3
is also regulated by oxygen tensions, in particular, during
the switch from early to late first trimester. This gestational
age-dependent dichotomy in cytokine production might be
explained by the fact that early placental development takes
place in the total absence of oxygen, as at that time, spiral
arteries remodeling is not fully complete, and the inter-
villous space is largely devoid of blood flow. But by the
end of the first trimester, maternal blood reaches the
placenta, and TGFβ3 production is down-regulated [121].
In contrast, TGFβ3 remains overexpressed in preeclamptic
placentas [122], a finding that may reflect the state of tissue
oxidative stress, but could also participate in the develop-
ment of later placental dysfunctions. Recently, it was shown
that IFN-γ synthesis by trophoblast cells similarly failed to
switch from high to low expression as placental environ-
ment switches from early hypoxic to late normoxic
condition [110].
Cytokines and placentation
During early pregnancy, the interstitial and endovascular
trophoblast cells, which invade the decidua and the lumen
of the uterine spiral arteries, respectively, differentiate from
a fraction of highly proliferative extravillous trophoblast
stem cells located in the anchoring villi. These differenti-
ated cells express a new repertoire of adhesion molecules
and secrete numerous proteinases, which enables their
migration through the uterine stoma and along the
endothelial lining of the vessels. In preeclampsia, invading
trophoblast cells exhibit an altered protease expression
profile and fail to acquire a vascular adhesion phenotype
[123, 124]. Remarkably, the proliferation, invasion, and
apoptosis of extravillous trophoblasts are orchestrated by
several growth factors and almost all cytokines present in
the intrauterine wall.
The switch in phenotype from a proliferative to an
invasive state appears to be principally controlled by
epidermal growth factor and hepatocyte growth factor
[125, 126]. This process is also very sensitive to oxygen
tension [127], possibly because of the overproduction of
cytokines and other mediators of angiogenesis by the
extravillous trophoblasts themselves. For instance, IL-1α,
IL-1β, and IL-6 have been described as positive regulators
of trophoblast differentiation along the invasive pathway as
these cytokines can stimulate matrix metalloproteinase
(MMP) 9 and MMP2 expression and activity [128, 129].
Specifically, IL-1β expression was shown to parallel the
invasive potential of cytotrophoblasts in vitro [130]. On the
contrary, IL-10 and TGFβ inhibit trophoblast production of
proteases and trophoblast invasion [131, 132]. Failure to
down-regulate TGFβ3 expression in proliferative cytotro-
phoblasts has been linked to shallow placentation and
Fig. 1 Placental villous explants were cultured for 24 h in the absence
(−) or in the presence (+) of vitamin C and levels of TNFα (left panel)
and IL-1β (right panel) secreted in the culture supernatant were
measured by enzyme linked immunosorbent assay and related to
explant wet weight. Paired Student t test was used. *p<0.05, N=10
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predisposes the pregnancy to preeclampsia [122]. TNFα
has also been implicated in the control of trophoblast cell
fate. Notably, TNFα, in combination with IFN-γ,
stimulates apoptosis of cultured cytotrophoblasts and
syncytiotrophoblasts [133, 134]. This suggests a mecha-
nism for deficient placentation in preeclampsia, where local
concentrations of both cytokines are high. In contrast,
conflicting results exist relative to the role of TNFα in
modulating extravillous trophoblast migration potential
[135, 136]. Nevertheless, the sum of these in vitro data
suggests that the unbalanced placental expression of several
cytokines early in pregnancies destined to develop pre-
eclampsia likely plays a role in the etiology of the disease.
TNFα also negatively affects the integrity of the
syncytiotrophoblast layer by stimulating increased apopto-
sis in vitro [137]. Under normoxia, the underlying
cytotrophoblasts were shown to reconstitute the syncytio-
trophoblast. In contrast, when the placental environment
was hypoxic, the syncytiotrophoblast failed to regenerate.
TNFα has also been reported to impair the syncytialization
process [138]. Thus, in preeclampsia, increased production
of TNFα by trophoblast cells in response to deficient
uteroplacental blood flow could, in an autocrine manner,
lead to continuous syncytiotrophoblast damage and
dysfunction. In addition, placental inflammation might be
triggered locally, via the release of TNFα after adhesion of
activated maternal monocytes to the syncytiotrophoblast
[139].
The placental expression of several gestational hormones
and mediators of metabolic pathways is also determined by
the local cytokine milieu [140]. This area of research has
been extensively studied in pregnancies affected with
obesity or diabetes mellitus, but less in pregnancies
complicated with preeclampsia. It is, nevertheless, likely
that the dysregulated expression of these molecules is also
occurring in preeclampsia as a result of the aberrant
placental cytokine production pattern hallmarking this
disease. However, this aspect will not be discussed here.
Cytokines and feto-placental tolerance
IL-10 and IL-4 are pleiotropic immunosuppressors, which
display inhibitory effects on cytotoxic and inflammatory
reactions. Their expression at the feto–maternal interface is
suggested to help in counteracting the harmful effects of
pro-inflammatory mediators on placental cells [141].
Remarkably, IL-10 also seems to be an important regulator
of trophoblast survival, as it has been shown to selectively
induces HLA-G expression in human cytotrophoblasts
[142]. In line with these results, low IL-10 levels and
diminished HLA-G expression have been observed in
preeclampsia. Hence, deficient placental IL-10 expression
might not only confer increased susceptibility to pro-
inflammatory signals but also amplify inflammation-driven
cell damage and NK cell-mediated trophoblast cell death.
By opposition, increased trophoblast production of IFN-γ
may account for the altered decidual lymphocyte subset
distribution and increased number of CD8-positive T cells
in the placental bed [143, 144]. IL-6 bears both pro- and
anti-inflammatory actions, depending on the cell type and
cellular microenvironment it acts on. In the placenta, IL-6
appears to be a positive regulator of pregnancy, as
trophoblast-derived IL-6 acts in an autocrine manner on
these cells to stimulate their secretion of the immunomod-
ulatory hormone, human chorionic gonadotropin (hCG)
[145]. However, serum levels of hCG are raised in
preeclamptic patients despite decreased placental IL-6
production, and the role of IL-6 in fetal tolerance awaits
elucidation.
Another possible player in promoting fetal tolerance is
the subset of CD4+CD25+ regulatory T lymphocytes. These
cells have been found to infiltrate the pregnant uterine wall
and are, in fact, the second largest population of maternal
immune cells present at the feto–maternal interface after
uterine NK cells [146]. They function by dampening T cell
mediated immune responses via the production of immu-
nosuppressive cytokines [147], and they possibly play a
role in the local maintenance of immune privilege [148].
Although preeclampsia is not associated with changes in
the levels of regulatory T cells at the periphery [149], the
cells may not perform adequately in this condition as
TNFα, which is expressed in excess both at the feto–
maternal interface and systemically, has been shown to
inhibit their suppressive function in vitro [150]. Whether
their numbers or activity is altered within the placentas of
preeclamptic patients remain to be established.
Cytokines and the maternal symptoms
The endothelium plays a major role in several processes
like the regulation of the coagulation cascade, the activation
of platelets and leukocyte function, and is therefore an
integral part of an inflammatory response. TNFα and IL-1
are the main pro-inflammatory cytokines that stimulate both
structural and functional alterations in endothelial cells
[151]. It has been suggested that placental IL-1 and TNFα
could be potential mediators of maternal endothelial
dysfunction in preeclampsia. The reasons for this are
multiple. First, the circulating concentration of both
cytokines is raised in pregnant women. In vitro, placentally
produced IL-1 alters human umbilical vein endothelial cell
proliferation and induces the secretion of soluble ICAM
and IL-6 [152]. The latter are indeed found in increased
levels in the peripheral blood of women with preeclampsia
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[153–155]. On the other hand, the elevated secretion of
TNFα by placental villous tissue in response to hypoxia/
reoxygenation causes a reduction of endothelial cell
viability and up-regulates the expression of the adhesion
molecule E-selectin by the endothelial cells [114]. Maternal
serum from preeclamptic patients also stimulates the
endothelial production of the vasoactive substances, endo-
thelin-1 and prostacyclin, which might maintain or amplify
maternal hypertension [156, 157]. According to recent
research, hypertension might be initially triggered by the
dysregulated placental production of the angiogenic factors
vascular endothelial growth factor (VEGF), soluble fms-
like tyrosine kinase (Flt)-1, and placental growth factor
(PlGF) [158, 159]. Serum from women with preeclampsia
also disrupts the membrane localization of cadherin-5,
which may decrease the number of adhesion complexes at
the cytoplasmic membrane and lead to vascular permeabil-
ity [160]. It remains to be established whether these
particular endothelial responses to serum are also mediated
by cytokines.
Despite these numerous findings, some have questioned
the idea that the maternal blood stream carries a placental
“toxic” factor to the periphery which contributes to
systemic maternal endothelial dysfunction, as they failed
to find any effect of plasma factors on endothelial gene
expression in vitro [161]. It has been suggested that the
activation of maternal leukocytes during their uteroplacen-
tal passage may instead play an important part in the
dissemination of an inflammatory response to the periphery
[162]. Leukocyte activation could be triggered by their
interaction with locally activated endothelium or placenta.
In favor of this hypothesis, it has been shown that
endothelial cells incubated with placental syncytiotropho-
blast debris release factors, which can activate peripheral
blood leukocytes in vitro [163]. It is interesting to note that
placental syncytiotrophoblast debris and placentally derived
IL-8 are also potent activators of neutrophils, in that they
stimulate the formation of neutrophil extracellular traps
(NET), made from DNA and granule proteins, by these
cells [164]. Large numbers of NETs are indeed present in
the intervillous space of preeclamptic placentas, demon-
strating the importance of local neutrophil activation in this
disease. Thus, two modes of propagation of the inflamma-
tory reaction from the placental site into the maternal
periphery, one encompassing soluble factors, among which
cytokines, and the other being cell-mediated, are possibly at
work in preeclampsia.
Conclusions
This review has attempted to describe how cytokine
networks are affected by pregnancy, and how in return,
these networks can affect the success of pregnancy.
Cytokines are involved throughout pregnancy, from the
implantation of the conceptus to parturition, including
placentation, and the maintenance of fetal tolerance. A
complete presentation of this large array of cytokine
requirements was beyond the scope of the present work.
We focused here on the role of placentally produced
cytokines on the maternal and fetal events, which are
substantially affected in preeclampsia, that is, placental
function and maternal inflammatory response to pregnancy.
It is clear that placental cytokines integrate into the general
maternal cytokine networks to modulate these events, and it
is most likely that positive feedback regulatory loops
between placental and maternal cells amplify the load of
cytokines present in the maternal body, and subsequently,
the maternal syndromes. In conclusion, dysregulated
cytokine expression by placental cells is certainly one facet
of the elusive placental “toxic” factor, or factors, causing
the maternal symptoms in preeclampsia.
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